| Original language | English (US) |
|---|---|
| Pages (from-to) | E26-E27 |
| Journal | Diabetes care |
| Volume | 43 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Feb 1 2020 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Diabetes care, Vol. 43, No. 2, 01.02.2020, p. E26-E27.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes
T2 - The WATCH-DM risk score. Diabetes Care 2019;42:2298-2306
AU - Segar, Matthew W.
AU - Vaduganathan, Muthiah
AU - McGuire, Darren K.
AU - Basit, Mujeeb
AU - Pandey, Ambarish
N1 - Funding Information: Funding and Duality of Interest. The Texas Health Resources Clinical Scholars Program funded this study. M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (National Institutes of Health National Center for Advancing Translational Science award UL1TR002541); serves on advisory boards for Amgen, Astra-Zeneca, Bayer AG, and Baxter Healthcare; and participates on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. D.K.M. has received personal fees for clinical trial leadership from GlaxoSmithKline, Janssen, Lexicon, AstraZeneca, Sanofi, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Eisai, Inc., Esperion, and Lilly USA and personal fees for consultancy from AstraZeneca, Lilly USA, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Metavant, Applied Therapeutics, Sanofi, and Afimmune. No other potential conflicts of interest relevant to this article were reported. Funding Information: The Texas Health Resources Clinical Scholars Program funded this study. M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (National Institutes of Health National Center for Advancing Translational Science award UL1TR002541); serves on advisory boards for Amgen, Astra-Zeneca, Bayer AG, and Baxter Healthcare; and participates on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. D.K.M. has received personal fees for clinical trial leadership from GlaxoSmithKline, Janssen, Lexicon, AstraZeneca, Sanofi, Boehringer Ingelheim, Merck & Co, Pfizer, Novo Nordisk, Eisai, Inc., Esperion, and Lilly USA and personal fees for consultancy from AstraZeneca, Lilly USA, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Metavant, Applied Therapeutics, Sanofi, and Afimmune. No other potential conflicts of interest relevant to this article were reported.
PY - 2020/2/1
Y1 - 2020/2/1
UR - http://www.scopus.com/inward/record.url?scp=85078618216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078618216&partnerID=8YFLogxK
U2 - 10.2337/dci19-0059
DO - 10.2337/dci19-0059
M3 - Comment/debate
C2 - 31959648
AN - SCOPUS:85078618216
SN - 0149-5992
VL - 43
SP - E26-E27
JO - Diabetes care
JF - Diabetes care
IS - 2
ER -